Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Tumor Board: Challenging Cases in Multiple Myeloma Patient Care

In this activity, a faculty panel will discuss real-world patient cases, leveraging their expertise and perspectives in a tumor board style exercise.

Available credits: 1.00


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The treatment armamentarium for MM has expanded significantly in recent years, with 4 new therapies approved by the FDA in 2015 alone. With so many agents and regimens to choose from, and more emerging therapies in clinical trials, it is crucial for oncology/hematology healthcare professionals to understand current treatment approaches for newly diagnosed and relapsed/refractory MM.

    In this activity, a faculty panel will convene to discuss real-world patient cases, leveraging their expertise and perspectives in a tumor board style exercise. The faculty panel will address some of the most pressing questions facing clinicians today when formulating the most appropriate treatment plans for their patients with MM. Current and emerging evidence-based updates will be integrated to assist in translating this array of information into real-world treatment scenarios and shed light on the progress toward answering many of the clinical challenges faced in MM treatment.

  • Target Audience

    This activity is designed for hematologists, medical oncologists, and other healthcare professionals who treat or manage patients with multiple myeloma.

  • Learning Objectives

    At the conclusion of this activity, participants should be able to:

    • Identify the differential diagnosis, prognostic factors, and cytogenetics of multiple myeloma (MM)
    • Evaluate current treatment modalities, in combination or alone, for newly diagnosed and relapsed/refractory MM to optimize patient outcomes
    • Assess recent clinical trial data on novel and emerging therapies for the treatment of MM and the implications of these agents on clinical practice
    • Explain appropriate strategies to manage adverse events and toxicities in patients with MM
  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest 
    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Paul G. Richardson, MD

    RJ Corman Professor of Medicine
    Harvard Medical School
    Clinical Program Leader, Director of Clinical Research
    Jerome Lipper Multiple Myeloma Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Member of advisory committee: Bristol-Myers Squibb Company; Celgene Corporation; Genmab; Johnson & Johnson; Millennium Takeda; Novartis Pharmaceuticals Corporation.

    Sergio A. Giralt, MD

    Chief, Adult Bone Marrow Transplant Service
    Melvin Berlin Family Chair in Myeloma Research
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Grant/Research support: Celgene Corporation; Johnson & Johnson; Sanofi; Honoraria: Amgen, Inc.; Celgene Corporation; Johnson & Johnson; Sanofi.

    Shaji K. Kumar, MD

    Professor of Medicine
    Mayo Clinic College of Medicine
    Consultant, Division of Hematology
    Mayo Clinic
    Rochester, Minnesota

    Consultant/Independent contractor: Kesios Therapeutics; NOXXON Pharma; Skyline Therapeutics Limited; Consultant/Independent contractor (all to Mayo Clinic - Rochester): Amgen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Grant/Research support (all to Mayo Clinic - Rochester): AbbVie; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Sanofi; Takeda Pharmaceutical Company Limited.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    • Andrea Funk has nothing to disclose. 
    • Laura Gilsdorf has nothing to disclose. 
    • Amanda Glazar, PhD has nothing to disclose. 
    • Linda Gracie-King, MS has nothing to disclose. 
    • Jocelyn Timko, BS has nothing to disclose. 
    • Isabelle Vacher has nothing to disclose. 
    • Ronald Viggiani, MD has nothing to disclose. 
  • Accreditation and Credit Designation Statements

    Continuing Medical Education

    Physician Accreditation Statement
    Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Physician Credit Designation 
    Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Instructions to Receive Credit

    In order to receive credit for this activity, during the period, 5/13/2016, through, 5/12/2017, participants must read the learning objectives and faculty disclosures, study the educational activity, and score a 75% or greater on the activity post-test. Your completed evaluation is requested.

    Fee Information & Refund/Cancellation Policy
    There is no fee for this educational activity.

    Global Contact Information
    For information about the accreditation of this program, please contact Global at 303-395-1782 or 

  • Provider(s)/Educational Partner(s)

    This activity is provided by Global Education Group.


  • Commercial Support

    This activity is supported by educational funding provided by Amgen.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and AXIS Medical Education do not recommend the use of any agent outside of the labeled indications.  

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.